



(51) International Patent Classification:

G16H 20/10 (2018.01) C12N 5/0783 (2010.01)
A61K 40/31 (2025.01)

(21) International Application Number:

PCT/IB2024/061731

(22) International Filing Date:

22 November 2024 (22.11.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/602,289	22 November 2023 (22.11.2023)	US
63/602,356	22 November 2023 (22.11.2023)	US
63/602,359	22 November 2023 (22.11.2023)	US
63/606,827	06 December 2023 (06.12.2023)	US
63/606,880	06 December 2023 (06.12.2023)	US

(71) Applicant: JANSSEN BIOTECH, INC. [US/US];
800/850 Ridgeview Drive, Horsham, Pennsylvania 19044
(US).

(72) Inventors: MAGGE RANGANATHA, Arjun; 920 US
Route 200, Raritan, New Jersey 08869 (US). JAVIDI, Alex;
920 US Route 200, Raritan, New Jersey 08869 (US). LU,
Hoang; 920 US Route 200, Raritan, New Jersey 08869

(US). HENCKELS, Eric; 920 US Route 200, Raritan, New
Jersey 08869 (US). CICCONE, Daniel; 1000 US Highway
202 S, Raritan, New Jersey 08869 (US). MORRIS, Don-
ald; 920 US Route 200, Raritan, New Jersey 08869 (US).
BOWDEN, Robert; 700 US Route 202, Raritan, New Jer-
sey 08869 (US).

(74) Agent: LANE, David A. et al.; JOHNSON & JOHNSON,
One Johnson & Johnson Plaza, New Brunswick, New Jersey
08933 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(54) Title: AI MODELS, SYSTEMS, AND METHODS FOR REDUCING GROWTH TERMINATIONS IN CAR T CELLS




FIG. 6A

(57) Abstract: Systems and methods are disclosed for predicting whether a patient-specific CAR T drug product for a target patient would undergo growth termination. An example method includes: receiving quantitative data for a set of growth termination parameters; generating an input feature vector comprising the quantitative data for the set of growth termination parameters; and applying, into a trained machine learning model, the input feature vector to generate an output feature vector predicting whether the patient-specific CAR T drug product would undergo growth termination.

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*